NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Adela

Adela

Private
Foster City, CaliforniaHealthcare & Life Scienceshttps://www.adelabio.com/

Last Round

Seed Round

Apr 23, 2026

Total Funding Raised

$108M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Adela is a healthcare technology company that develops blood-based diagnostic tests for minimal residual disease monitoring and multi-cancer early detection using a genome-wide methylome enrichment platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Clinical Trials, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

liquid biopsyMRDminimal residual diseasecfDNAcell-free DNAcancer detectionMCEDmulti-cancer early detectionimmunotherapy monitoringprecision medicineblood-based cancer testgenomic cancer detectiontissue-free biopsydiagnostic assayoncology diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Adela Comparables

Compare Adela with similar companies based on industry and business-model similarity.

Adela comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Exai Bio
86%
Lucence
85%
Delfi Diagnostics
84%

Adela Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundApr 23, 2026
Seed RoundFeb 14, 2024
Seed RoundFeb 14, 2024
Series A ExtensionSep 25, 2023
Series AJun 23, 2021

Key People

Founding team and executive leadership

Anne-Renee Hartman

Co-founder And Chief Medical Officer

Founding Team

Daniel De Carvalho

Chief Scientific Officer, Co-Founder

Founding Team

Lisa Alderson

Chief Executive Officer

Executive Team

Adela Investors

Notable investors and investment history

Adela investors
InvestorRounds
Deerfield ManagementSeries A Extension, Series A
RA Capital ManagementSeries A Extension, Series A
F-Prime CapitalSeries A Extension, Series A
OrbiMedSeries A Extension, Series A
F-Prime CapitalSeries A Extension, Series A
Decheng CapitalSeries A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    $5M round raised.

  • Mar 26, 2026

    Tissue-free liquid biopsy assay nearing commercialization for a new indication.

Adela Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Adela Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Adela's valuation, stock price, and market status.

Firmographic Details

HeadquartersFoster City, California
Employee Range70
Year Founded2020
Last FundingApr 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.